The EU continues to invest in CombiGene

2021   2020   2019   2018   2017   2016   2015   This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> CombiGene’s epilepsy project CG01 has already been granted EUR 3.36 million by the EU programme Horizon 2020. Now the EU is...

read more

Gunilla Lundmark new board member of CombiGene

News 2021 2021   2020   2019   2018   2017   2016   2015 At CombiGene’s Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions...

read more

First in human study within reach

News 2021 2021   2020   2019   2018   2017   2016   2015   This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> A lot has happened at CombiGene during the first months of 2021 and when Ingeneious gets the opportunity to talk to...

read more

CombiGene annual report 2020

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013 Annual report 2020>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene...

read more

Ingeneious #1 2021, News from CombiGene

Ingeneious 2021 2021   2020   2019   2018   2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement...

read more

Year-end statement 2020

Financial reports 2020 2021   2020   2019   2018   2017   2016   2015   2014   2013 Year-end statement 2020 >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook